{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T13:36:12Z","timestamp":1790516172135,"version":"4.1.0"},"reference-count":51,"publisher":"Springer Science and Business Media LLC","issue":"1","content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arthritis Res Ther"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1186\/s13075-018-1537-8","type":"journal-article","created":{"date-parts":[[2018,3,1]],"date-time":"2018-03-01T01:18:50Z","timestamp":1519867130000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":37,"title":["Pharmacological characterisation of CR6086, a potent prostaglandin E2 receptor 4 antagonist, as a new potential disease-modifying anti-rheumatic drug"],"prefix":"10.1186","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1075-7408","authenticated-orcid":false,"given":"Gianfranco","family":"Caselli","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Albino","family":"Bonazzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Lanza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Flora","family":"Ferrari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniele","family":"Maggioni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristian","family":"Ferioli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"Giambelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eleonora","family":"Comi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Zerbi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Perrella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ornella","family":"Letari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Di Luccio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Milena","family":"Colovic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefano","family":"Persiani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tiziano","family":"Zanelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Mennuni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tiziana","family":"Piepoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucio Claudio","family":"Rovati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,3,1]]},"reference":[{"key":"1537_CR1","doi-asserted-by":"crossref","first-page":"R7","DOI":"10.1186\/ar2591","volume":"11","author":"T Sokka","year":"2009","unstructured":"Sokka T, Toloza S, Cutolo M, Kautiainen H, Makinen H, Gogus F, et al. Women, men, and rheumatoid arthritis: analyses of disease activity, disease characteristics, and treatments in the QUEST-RA study. Arthritis Res Ther. 2009;11:R7.","journal-title":"Arthritis Res Ther."},{"key":"1537_CR2","volume-title":"Guideline on clinical investigation of medicinal products other than NSAIDs for treatment of rheumatoid arthritis. CPMP\/EWP\/556\/95 Rev. 2 (Draft)","author":"European Medicines Agency (EMA), Committee for Medicinal Products for Human Use (CHMP)","year":"2015","unstructured":"European Medicines Agency (EMA), Committee for Medicinal Products for Human Use (CHMP). Guideline on clinical investigation of medicinal products other than NSAIDs for treatment of rheumatoid arthritis. CPMP\/EWP\/556\/95 Rev. 2 (Draft). London: EMA; 2015."},{"key":"1537_CR3","doi-asserted-by":"publisher","first-page":"986","DOI":"10.1016\/j.apmr.2013.10.032","volume":"95","author":"VY Ma","year":"2014","unstructured":"Ma VY, Chan L, Carruthers KJ. Incidence, prevalence, costs, and impact on disability of common conditions requiring rehabilitation in the United States: stroke, spinal cord injury, traumatic brain injury, multiple sclerosis, osteoarthritis, rheumatoid arthritis, limb loss, and back pain. Arch Phys Med Rehabil. 2014;95:986\u201395.","journal-title":"Arch Phys Med Rehabil."},{"key":"1537_CR4","doi-asserted-by":"publisher","first-page":"2023","DOI":"10.1016\/S0140-6736(16)30173-8","volume":"388","author":"JS Smolen","year":"2016","unstructured":"Smolen JS, Aletaha D, McInnes IB. Rheumatoid arthritis. Lancet. 2016;388:2023\u201338.","journal-title":"Lancet."},{"key":"1537_CR5","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1136\/annrheumdis-2013-204573","volume":"73","author":"JS Smolen","year":"2014","unstructured":"Smolen JS, Landew\u00e9 R, Breedveld FC, Buch M, Burmester G, Dougados M, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update. Ann Rheum Dis. 2014;73:492\u2013509.","journal-title":"Ann Rheum Dis."},{"key":"1537_CR6","first-page":"1","volume":"68","author":"JA Singh","year":"2016","unstructured":"Singh JA, Saag KG, Bridges SL Jr, Akl EA, Bannuru RR, Sullivan MC, et al. 2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis. Arthritis Rheumatol. 2016;68:1\u201326.","journal-title":"Arthritis Rheumatol."},{"key":"1537_CR7","doi-asserted-by":"publisher","first-page":"2095","DOI":"10.1517\/14656560903071043","volume":"10","author":"MG Feely","year":"2009","unstructured":"Feely MG, Erickson A, O\u2019Dell JR. Therapeutic options for rheumatoid arthritis. Expert Opin Pharmacother. 2009;10:2095\u2013106.","journal-title":"Expert Opin Pharmacother."},{"key":"1537_CR8","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1016\/j.tips.2012.02.004","volume":"33","author":"T Aoki","year":"2012","unstructured":"Aoki T, Narumiya S. Prostaglandins and chronic inflammation. Trends Pharmacol Sci. 2012;33:304\u201311.","journal-title":"Trends Pharmacol Sci."},{"issue":"Suppl 1","key":"1537_CR9","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1186\/ar2412","volume":"10","author":"AP Cope","year":"2008","unstructured":"Cope AP. T cells in rheumatoid arthritis. Arthritis Res Ther. 2008;10(Suppl 1):S1.","journal-title":"Arthritis Res Ther."},{"key":"1537_CR10","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s12016-015-8515-6","volume":"51","author":"R Baum","year":"2016","unstructured":"Baum R, Gravallese EM. Bone as a target organ in rheumatic disease: impact on osteoclasts and osteoblasts. Clin Rev Allergy Immunol. 2016;51:1\u201315.","journal-title":"Clin Rev Allergy Immunol."},{"key":"1537_CR11","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1111\/j.1476-5381.2010.00647.x","volume":"160","author":"Q Chen","year":"2010","unstructured":"Chen Q, Muramoto K, Masaaki N, Ding Y, Yang H, Mackey M, et al. A novel antagonist of the prostaglandin E2 EP4 receptor inhibits Th1 differentiation and Th17 expansion and is orally active in arthritis models. Br J Pharmacol. 2010;160:292\u2013310.","journal-title":"Br J Pharmacol."},{"key":"1537_CR12","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1124\/pr.110.003517","volume":"63","author":"DF Woodward","year":"2011","unstructured":"Woodward DF, Jones RL, Narumiya S. International Union of Basic and Clinical Pharmacology. LXXXIII: Classification of prostanoid receptors, updating 15 years of progress. Pharmacol Rev. 2011;63:471\u2013538.","journal-title":"Pharmacol Rev."},{"key":"1537_CR13","doi-asserted-by":"publisher","first-page":"1010","DOI":"10.1124\/pr.112.007195","volume":"65","author":"U Yokoyama","year":"2013","unstructured":"Yokoyama U, Iwatsubo K, Umemura M, Fujita T, Ishikawa Y. The prostanoid EP4 receptor and its signaling pathway. Pharmacol Rev. 2013;65:1010\u201352.","journal-title":"Pharmacol Rev."},{"key":"1537_CR14","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1038\/nm.1968","volume":"15","author":"C Yao","year":"2009","unstructured":"Yao C, Sakata D, Esaki Y, Li Y, Matsuoka T, Kuroiwa K, et al. Prostaglandin E2\u2013EP4 signaling promotes immune inflammation through TH1 cell differentiation and TH17 cell expansion. Nat Med. 2009;15:633\u201340.","journal-title":"Nat Med."},{"key":"1537_CR15","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1254\/jphs.09R03CP","volume":"112","author":"D Sakata","year":"2010","unstructured":"Sakata D, Yao C, Narumiya S. Prostaglandin E2, an immunoactivator. J Pharmacol Sci. 2010;112:1\u20135.","journal-title":"J Pharmacol Sci."},{"key":"1537_CR16","doi-asserted-by":"publisher","first-page":"1362","DOI":"10.1182\/blood-2001-12-0360","volume":"100","author":"T Luft","year":"2002","unstructured":"Luft T, Jefford M, Luetjens P, Toy T, Hochrein H, Masterman KA, et al. Functionally distinct dendritic cell (DC) populations induced by physiologic stimuli: prostaglandin E2 regulates the migratory capacity of specific DC subsets. Blood. 2002;100:1362\u201372.","journal-title":"Blood."},{"key":"1537_CR17","doi-asserted-by":"publisher","first-page":"966","DOI":"10.4049\/jimmunol.176.2.966","volume":"176","author":"DF Legler","year":"2006","unstructured":"Legler DF, Krause P, Scandella E, Singer E, Groettrup M. Prostaglandin E2 is generally required for human dendritic cell migration and exerts its effect via EP2 and EP4 receptors. J Immunol. 2006;176:966\u201373.","journal-title":"J Immunol."},{"key":"1537_CR18","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1172\/JCI0215528","volume":"110","author":"JM McCoy","year":"2002","unstructured":"McCoy JM, Wicks JR, Audoly LP. The role of prostaglandin E2 receptors in the pathogenesis of rheumatoid arthritis. J Clin Invest. 2002;110:651\u20138.","journal-title":"J Clin Invest."},{"key":"1537_CR19","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1002\/iub.356","volume":"62","author":"D Sakata","year":"2010","unstructured":"Sakata D, Yao C, Narumiya S. Emerging roles of prostanoids in T cell-mediated immunity. IUBMB Life. 2010;62:591\u20136.","journal-title":"IUBMB Life."},{"key":"1537_CR20","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1054\/plef.1999.0127","volume":"64","author":"P Sarrazin","year":"2001","unstructured":"Sarrazin P, Bkaily G, Hach\u00e9 R, Patry C, Dumais R, Rocha FA, et al. Characterization of the prostaglandin receptors in human osteoblasts in culture. Prostaglandins Leukot Essent Fatty Acids. 2001;64:203\u201310.","journal-title":"Prostaglandins Leukot Essent Fatty Acids."},{"issue":"5","key":"1537_CR21","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1016\/j.tem.2009.12.004","volume":"21","author":"KA Blackwell","year":"2010","unstructured":"Blackwell KA, Raisz LG, Pilbeam CC. Prostaglandins in bone: bad cop, good cop? Trends Endocrinol Metab. 2010;21(5):294\u2013301.","journal-title":"Trends Endocrinol Metab."},{"key":"1537_CR22","doi-asserted-by":"publisher","first-page":"2608","DOI":"10.1002\/art.22794","volume":"56","author":"AF Sheibanie","year":"2007","unstructured":"Sheibanie AF, Khayrullina T, Safadi FF, Ganea D. Prostaglandin E2 exacerbates collagen-induced arthritis in mice through the inflammatory interleukin-23\/interleukin-17 axis. Arthritis Rheum. 2007;56:2608\u201319.","journal-title":"Arthritis Rheum."},{"issue":"2","key":"1537_CR23","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1016\/S1388-1981(99)00164-X","volume":"1483","author":"M Abramovitz","year":"2000","unstructured":"Abramovitz M, Adam M, Boie Y, Carri\u00e8re M, Denis D, Godbout C, et al. The utilization of recombinant prostanoid receptors to determine the affinities and selectivities of prostaglandins and related analogs. Biochim Biophys Acta. 2000;1483(2):285\u201393.","journal-title":"Biochim Biophys Acta."},{"issue":"1","key":"1537_CR24","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1177\/019262339902700125","volume":"27","author":"A Bendele","year":"1999","unstructured":"Bendele A, McComb J, Gould T, McAbee T, Sennello G, Chlipala E, et al. Animal models of arthritis: relevance to human disease. Toxicol Pathol. 1999;27(1):134\u201342.","journal-title":"Toxicol Pathol."},{"issue":"5","key":"1537_CR25","doi-asserted-by":"publisher","first-page":"1269","DOI":"10.1038\/nprot.2007.173","volume":"2","author":"DD Brand","year":"2007","unstructured":"Brand DD, Latham KA, Rosloniec EF. Collagen-induced arthritis. Nat Protoc. 2007;2(5):1269\u201375.","journal-title":"Nat Protoc."},{"issue":"2","key":"1537_CR26","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1038\/sj.bjp.0701367","volume":"122","author":"M Kiriyama","year":"1997","unstructured":"Kiriyama M, Ushikubi F, Kobayashi T, Hirata M, Sugimoto Y, Narumiya S. Ligand binding specificities of the eight types and subtypes of the mouse prostanoid receptors expressed in Chinese hamster ovary cells. Br J Pharmacol. 1997;122(2):217\u201324.","journal-title":"Br J Pharmacol."},{"issue":"2\u20133","key":"1537_CR27","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1016\/S0014-2999(97)01383-6","volume":"340","author":"Y Boie","year":"1997","unstructured":"Boie Y, Stocco R, Sawyer N, Slipetz DM, Ungrin MD, Neusch\u00e4fer-Rube F, et al. Molecular cloning and characterization of the four rat prostaglandin E2 prostanoid receptor subtypes. Eur J Pharmacol. 1997;340(2\u20133):227\u201341.","journal-title":"Eur J Pharmacol"},{"issue":"1\u20132","key":"1537_CR28","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1016\/j.ejphar.2007.10.054","volume":"580","author":"A Murase","year":"2008","unstructured":"Murase A, Okumura T, Sakakibara A, Tonai-Kachi H, Nakao K, Takada J. Effect of prostanoid EP4 receptor antagonist, CJ-042,794, in rat models of pain and inflammation. Eur J Pharmacol. 2008;580(1\u20132):116\u201321.","journal-title":"Eur J Pharmacol."},{"key":"1537_CR29","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1186\/s12885-016-3018-2","volume":"17","author":"P Nandi","year":"2017","unstructured":"Nandi P, Girish GV, Majumder M, Xin X, Tutunea-Fatan E, Lala PK. PGE2 promotes breast cancer-associated lymphangiogenesis by activation of EP4 receptor on lymphatic endothelial cells. BMC Cancer. 2017;17:11.","journal-title":"BMC Cancer."},{"key":"1537_CR30","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.plefa.2016.01.005","volume":"106","author":"A Bonanno","year":"2016","unstructured":"Bonanno A, Albano GD, Siena L, Montalbano AM, Riccobono L, Anzalone G, et al. Prostaglandin E2 possesses different potencies in inducing vascular endothelial growth factor and interleukin-8 production in COPD human lung fibroblasts. Prostaglandins Leukot Essent Fatty Acids. 2016;106:11\u20138.","journal-title":"Prostaglandins Leukot Essent Fatty Acids."},{"key":"1537_CR31","first-page":"357904","volume":"2013","author":"H Ni","year":"2013","unstructured":"Ni H, Moe S, Myint KT, Htet A. Oral Janus kinase inhibitor for the treatment of rheumatoid arthritis: tofacitinib. ISRN Rheumatol. 2013;2013:357904.","journal-title":"ISRN Rheumatol."},{"issue":"3\u20134","key":"1537_CR32","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1007\/BF01986577","volume":"33","author":"JT Hom","year":"1991","unstructured":"Hom JT, Gliszczynski VL, Cole HW, Bendele AM. Interleukin 1 mediated acceleration of type II collagen-induced arthritis: effects of anti-inflammatory or anti-arthritic drugs. Agents Actions. 1991;33(3\u20134):300\u20139.","journal-title":"Agents Actions."},{"issue":"5","key":"1537_CR33","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1124\/dmd.116.074526","volume":"45","author":"X Li","year":"2017","unstructured":"Li X, DuBois DC, Almon RR, Jusko WJ. Modeling sex differences in pharmacokinetics, pharmacodynamics, and disease progression effects of naproxen in rats with collagen-induced arthritis. Drug Metab Dispos. 2017;45(5):484\u201391.","journal-title":"Drug Metab Dispos."},{"key":"1537_CR34","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/0162-3109(85)90059-1","volume":"10","author":"K Phadke","year":"1985","unstructured":"Phadke K, Fouts RL, Parrish JE, Butler LD. Evaluation of the effects of various anti-arthritic drugs on type II collagen-induced mouse arthritis model. Immunopharmacology. 1985;10:51\u201360.","journal-title":"Immunopharmacology."},{"key":"1537_CR35","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1016\/S1357-4310(99)01528-2","volume":"5","author":"B Joe","year":"1999","unstructured":"Joe B, Wilder RL. Animal models of rheumatoid arthritis. Mol Med Today. 1999;5:367\u20139.","journal-title":"Mol Med Today."},{"issue":"11","key":"1537_CR36","doi-asserted-by":"publisher","first-page":"1505","DOI":"10.1136\/ard.2007.076430","volume":"67","author":"M Hegen","year":"2008","unstructured":"Hegen M, Keith JC Jr, Collins M, Nickerson-Nutter CL. Utility of animal models for identification of potential therapeutics for rheumatoid arthritis. Ann Rheum Dis. 2008;67(11):1505\u201315.","journal-title":"Ann Rheum Dis."},{"key":"1537_CR37","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1002\/art.1780390320","volume":"39","author":"CL Nickerson-Nutter","year":"1996","unstructured":"Nickerson-Nutter CL, Medvedeff ED. The effect of leukotriene synthesis inhibitors in models of acute and chronic inflammation. Arthritis Rheum. 1996;39:515\u201321.","journal-title":"Arthritis Rheum."},{"key":"1537_CR38","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1046\/j.1365-2249.1998.00529.x","volume":"111","author":"L Svensson","year":"1998","unstructured":"Svensson L, Jirholt J, Holmdahl R, Jansson L. B cell-deficient mice do not develop type II collagen-induced arthritis (CIA). Clin Exp Immunol. 1998;111:521\u20136.","journal-title":"Clin Exp Immunol."},{"key":"1537_CR39","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1038\/sj.bjp.0704705","volume":"136","author":"H Inoue","year":"2002","unstructured":"Inoue H, Takamori M, Shimoyama Y, Ishibashi H, Yamamoto S, Koshihara Y. Regulation by PGE2 of the production of interleukin-6, macrophage colony stimulating factor, and vascular endothelial growth factor in human synovial fibroblasts. Br J Pharmacol. 2002;136:287\u201395.","journal-title":"Br J Pharmacol."},{"key":"1537_CR40","doi-asserted-by":"publisher","first-page":"383","DOI":"10.2174\/187153006779025711","volume":"6","author":"J Akaogi","year":"2006","unstructured":"Akaogi J, Nozaki T, Satoh M, Yamada H. Role of PGE2 and EP receptors in the pathogenesis of rheumatoid arthritis and as a novel therapeutic strategy. Endocr Metab Immune Disord Drug Targets. 2006;6:383\u201394.","journal-title":"Endocr Metab Immune Disord Drug Targets."},{"issue":"3","key":"1537_CR41","doi-asserted-by":"publisher","first-page":"e00316","DOI":"10.1002\/prp2.316","volume":"5","author":"S Chandrasekhar","year":"2017","unstructured":"Chandrasekhar S, Yu XP, Harvey AK, Oskins JL, Lin C, Wang X, et al. Analgesic and anti-inflammatory properties of novel, selective, and potent EP4 receptor antagonists. Pharmacol Res Perspect. 2017;5(3):e00316.","journal-title":"Pharmacol Res Perspect."},{"key":"1537_CR42","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/j.plipres.2007.12.003","volume":"47","author":"H Hikiji","year":"2008","unstructured":"Hikiji H, Takato T, Shimizu T, Ishii S. The roles of prostanoids, leukotrienes, and platelet-activating factor in bone metabolism and disease. Prog Lipid Res. 2008;47:107\u201326.","journal-title":"Prog Lipid Res."},{"key":"1537_CR43","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.1159\/000453165","volume":"40","author":"S Jiang","year":"2016","unstructured":"Jiang S, Li Y, Lin T, Yuan L, Li Y, Wu S, et al. IL-35 inhibits angiogenesis through VEGF\/Ang2\/Tie2 pathway in rheumatoid arthritis. Cell Physiol Biochem. 2016;40:1105\u201316.","journal-title":"Cell Physiol Biochem."},{"key":"1537_CR44","doi-asserted-by":"publisher","first-page":"40274","DOI":"10.1038\/srep40274","volume":"7","author":"Y Lu","year":"2017","unstructured":"Lu Y, Yu SS, Zong M, Fan SS, Lu TB, Gong RH, et al. Glucose-6-phosphate isomerase (G6PI) mediates hypoxia-induced angiogenesis in rheumatoid arthritis. Sci Rep. 2017;7:40274.","journal-title":"Sci Rep."},{"issue":"1","key":"1537_CR45","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.jbspin.2009.05.011","volume":"77","author":"Z Szekanecz","year":"2010","unstructured":"Szekanecz Z, Besenyei T, Paragh G, Koch AE. New insights in synovial angiogenesis. Joint Bone Spine. 2010;77(1):13\u20139.","journal-title":"Joint Bone Spine."},{"key":"1537_CR46","volume-title":"Cytokine frontiers: regulation of immune responses in health and disease","year":"2014","unstructured":"Yoshimoto T, Yoshimoto T, editors. Cytokine frontiers: regulation of immune responses in health and disease. 1st ed. Tokyo: Springer Japan; 2014.","edition":"1"},{"key":"1537_CR47","doi-asserted-by":"publisher","first-page":"4015","DOI":"10.1002\/art.23063","volume":"56","author":"JJ Inglis","year":"2007","unstructured":"Inglis JJ, Notley CA, Essex D, Wilson AW, Feldmann M, Anand P, et al. Collagen-induced arthritis as a model of hyperalgesia: functional and cellular analysis of the analgesic actions of tumor necrosis factor blockade. Arthritis Rheum. 2007;56:4015\u201323.","journal-title":"Arthritis Rheum."},{"key":"1537_CR48","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1186\/s12974-016-0556-0","volume":"13","author":"FR Nieto","year":"2016","unstructured":"Nieto FR, Clark AK, Grist J, Hathway GJ, Chapman V, Malcangio M. Neuron-immune mechanisms contribute to pain in early stages of arthritis. J Neuroinflammation. 2016;13:96.","journal-title":"J Neuroinflammation."},{"key":"1537_CR49","unstructured":"Piepoli T, Maggioni D, Zerbi S, Stucchi A, Mennuni L, Lanza M, Caselli G, Rovati LC. CR6086: a new potent EP4 receptor antagonist with immunomodulatory activities [abstract 2262]. Arthritis Rheum. 2016;68(10 Suppl)"},{"key":"1537_CR50","unstructured":"Piepoli T, Montagna M, Maggioni D, Zerbi S, Mennuni L, Lanza M, Caselli G, Rovati LC. In vitro effects of CR6086, a potent prostaglandin E2 subtype 4 receptor antagonist, on bone erosive pathways [abstract 955]. Arthritis Rheum. 2017;69(10 Suppl)"},{"key":"1537_CR51","unstructured":"Caselli G, Ferrari F, Comi E, Perrella M, Recordati C, Grotti A, Cavagnoli R, Lanza M, Rovati LC. CR6086 is highly effective and improves methotrexate effect in a mouse model of rheumatoid arthritis [abstract 408]. Arthritis Rheum. 2017;69(10 Suppl)"}],"container-title":["Arthritis Research & Therapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13075-018-1537-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,2]],"date-time":"2025-07-02T04:32:21Z","timestamp":1751430741000},"score":1,"resource":{"primary":{"URL":"https:\/\/arthritis-research.biomedcentral.com\/articles\/10.1186\/s13075-018-1537-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,3,1]]},"references-count":51,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["1537"],"URL":"https:\/\/doi.org\/10.1186\/s13075-018-1537-8","relation":{},"ISSN":["1478-6362"],"issn-type":[{"value":"1478-6362","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,3,1]]},"assertion":[{"value":"21 November 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 February 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 March 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"PBMCs were prepared using whole blood obtained from healthy volunteers upon receiving their informed consent. Because the study presented no material ethical issues (samples anonymised and discarded immediately after analysis), the procedure was approved by the internal research ethics advisor. Animal studies were carried out in compliance with national and international laws and policies (Italian Legislative Decree 116\/1992, and 26\/2014 that transposed the EU Directive 86\/609, and 2010\/63\/EU on the protection of animals used for scientific purposes) and were authorised by the Italian Ministry of Health (Decr. Min. number 60\/2009-B, Decr. Min. number 214\/2013-B, and Decr. Min. number 561\/2017-PR).","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"All of the authors are employees of Rottapharm Biotech.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"39"}}